Crispr Therapeutics AG (NASDAQ:CRSP) was the recipient of unusually large options trading activity on Tuesday. Investors acquired 4,694 put options on the stock. This is an increase of approximately 804% compared to the typical volume of 519 put options.

NASDAQ:CRSP opened at $35.06 on Thursday. Crispr Therapeutics has a 52 week low of $17.40 and a 52 week high of $73.90. The company has a market cap of $1.77 billion, a P/E ratio of -20.50 and a beta of 3.75.

Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Thursday, November 8th. The company reported ($1.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.33). Crispr Therapeutics had a negative net margin of 331.84% and a negative return on equity of 40.41%. The firm had revenue of $0.56 million for the quarter, compared to analysts’ expectations of $2.64 million. During the same period in the previous year, the company earned ($0.62) EPS. The company’s revenue was down 76.6% on a year-over-year basis. As a group, equities analysts forecast that Crispr Therapeutics will post -3.26 EPS for the current fiscal year.

Several brokerages have recently weighed in on CRSP. Citigroup lowered their price target on shares of Crispr Therapeutics from $51.00 to $50.00 and set a “neutral” rating for the company in a research report on Friday, August 24th. Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 10th. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research report on Monday, September 17th. Guggenheim initiated coverage on shares of Crispr Therapeutics in a research report on Tuesday, October 9th. They set a “neutral” rating for the company. Finally, BidaskClub cut shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 26th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $62.47.

A number of large investors have recently bought and sold shares of CRSP. Rockefeller Capital Management L.P. purchased a new stake in Crispr Therapeutics during the second quarter valued at approximately $116,000. TRUE Private Wealth Advisors acquired a new position in Crispr Therapeutics during the 3rd quarter valued at approximately $122,000. Signaturefd LLC increased its stake in Crispr Therapeutics by 123.8% during the 2nd quarter. Signaturefd LLC now owns 2,350 shares of the company’s stock valued at $138,000 after purchasing an additional 1,300 shares in the last quarter. First Mercantile Trust Co. acquired a new position in Crispr Therapeutics during the 2nd quarter valued at approximately $141,000. Finally, SeaCrest Wealth Management LLC increased its stake in Crispr Therapeutics by 202.9% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 2,726 shares of the company’s stock valued at $160,000 after purchasing an additional 1,826 shares in the last quarter. 40.19% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Investors Buy Large Volume of Crispr Therapeutics Put Options (CRSP)” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/11/21/investors-buy-large-volume-of-crispr-therapeutics-put-options-crsp.html.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Read More: Stock Selection – What is cash flow?

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.